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Abstract
The oncofoetal antigen 5T4 is a promising T cell target in the context of colorectal cancer, as demonstrated by a recent 
clinical study where 5T4-specific T cell responses, induced by vaccination or cyclophosphamide, were associated with a 
significantly prolonged survival of patients with metastatic disease. Whilst Th1-type (IFN-γ+) responses specific to 5T4, 
and other oncofoetal antigens, are often readily detectable in early stage CRC patients and healthy donors, their activity is 
suppressed as the cancer progresses by  CD4+CD25hiFoxp3+ regulatory T cells (Treg) which contribute to the immunosup-
pressive environment conducive to tumour growth. This study mapped the fine specificity of Th1 and Treg cell responses 
to the 5T4 protein. Surprisingly, both immunogenic peptides and those recognised by Tregs clustered in the same HLA-DR 
transcending epitope-rich hotspots within the 5T4 protein. Similarly, regions of low Th1-cell immunogenicity also did not 
contain peptides capable of stimulating Tregs, further supporting the notion that Treg and Th1 cells recognise the same 
peptides. Understanding the rules which govern the balance of Th1 and Treg cells responding to a given peptide specificity 
is, therefore, of fundamental importance to designing strategies for manipulating the balance in favour of Th1 cells, and thus 
the most effective anti-cancer T cell responses.
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Introduction
Despite evidence that progression of human colorectal 
cancer (CRC) can be controlled by greater infiltration of 
T cells into the tumour [2], responses to immune-based co-
inhibitory receptor (checkpoint) blockade and vaccines in 
CRC patients harbouring  MSI− tumours remain very poor 
[3]. Vaccination, which depends on the identification of 
tumour antigens, may prove more effective for the treat-
ment of CRC, particularly in conjunction with immune-
modulators. To be effective, a vaccine should induce a 
robust cytotoxic  CD8+ T cell (CTLs) response as well as a 
Th1-type  CD4+ T cell response. Whilst CTLs can directly 
recognise and kill tumour cells, provided they express 
MHC class I molecules,  CD4+ T cells provide help, but 
also contribute directly to tumour eradication via direct 
cytotoxic effects, induction of senescence, or indirect IFN-
γ-mediated potentiation of tumouricidal macrophages and 
inhibition of angiogenesis [4].
Although tumour-specific responses are frequently 
induced after vaccination, these effects do not often lead 
to improved clinical outcomes. Interrogations of this 
limited therapeutic efficacy implicate tumour-induced 
 CD4+CD25hiFoxp3+ T cells (Treg) in suppressing the 
development of effective anti-tumour immune responses 
[5–7]. Notably tumour-specific epitopes including LAGE-
1108–120, recognised by melanoma infiltrating Treg [8], and 
 gp100369–383, recognised by circulating Treg [9], have been 
identified. Therefore, vaccination with tumour-specific 
peptides may unintentionally inhibit the activation of Th1 
cells if tumour antigen-specific Treg are also activated. An 
NY-ESO-1/ISCOMATRIX™ peptide-based vaccine has 
been shown to increase pre-existing Treg responses against 
the NY-ESO-1 tumour antigen resulting in inhibition of 
 CD8+ T cell proliferation in vitro [10]. Moreover, Welters 
and colleagues previously showed that vaccination with 
HPV-derived long peptides could induce HPV-specific 
Treg in patients with vulvar and cervical cancers [11, 12].
In this study, we set out to determine whether it is pos-
sible to deconstruct the T cell response to a cancer antigen 
to preserve the ability to stimulate IFN-γ+ T cells whilst 
reducing its capacity to stimulate a Treg response. To 
do this, we chose the oncofoetal antigen, 5T4, which is 
a transmembrane glycoprotein expressed in human pla-
centa, absent in other normal tissues, but overexpressed 
by many adenocarcinomas of the lung, breast and colon 
[13, 14]. We have previously shown that 5T4-specific T 
cell responses are observed in around 70% of CRC patients 
and that these responses decline with disease progression, 
partly because of Treg activity [15]. In addition, the find-
ings of a recent Phase I/II clinical study performed by 
our group, indicate that 5T4-specific T cells may confer 
protection against progression of CRC [16]. 5T4 is, there-
fore, a relevant candidate antigen for cancer immunother-
apy. We explored the immunogenicity of 5T4 with the aim 
of identifying regions of the protein able to induce IFN-γ+ 
T cells in a diverse population comprising individuals with 
and without CRC. Furthermore, the ability of Treg popu-
lations to modulate these responses and the specificity of 
their action was investigated.
Materials and methods
Patients
Sixty-four patients undergoing colectomy for the removal of 
a primary colorectal adenocarcinoma were consented before 
surgery to obtain 30–50 mL peripheral blood samples, col-
lected in 10 mL lithium heparin tubes (BD Biosciences). 
HLA-type was determined from these samples (Welsh 
Transplantation and Immunogenetics Laboratory).
Synthetic peptides
Forty-one 20mer peptides overlapping by 10 amino acids 
and spanning the entire 5T4 protein were synthesised to 
> 95% purity (GLBiochem), the sequences of these peptides 
are shown (Supplementary Table 1). Peptides were dissolved 
in DMSO at 50 mg/mL and diluted in PBS to 1 mg/mL 
before use. 13 peptide pools, containing 5–7 peptides, were 
created in a matrix system where each peptide was present in 
2 pools (Fig. 1a). Peptides were added at a final concentra-
tion of 5 µg/mL peptide for T cell assays.
Lymphocyte purification and culture
Peripheral blood mononuclear cells (PBMCs) were isolated 
by centrifugation of heparinised blood over Lymphoprep 
(Axis-Shield). Cells were then washed and re-suspended at a 
concentration of 2 × 106 cells/mL in RPMI (Thermo Fisher) 
supplemented with 5% batch-tested, pooled human AB 
serum (Welsh Blood Service), l-glutamine and penicillin/
streptomycin. PBMC were plated at 100 µL/well in 96-well 
plates (Nunc) and cultured in triplicate wells with each 5T4 
peptide pool or single 5T4 peptide for 14 days (37 °C, 5% 
 CO2). Cells were supplemented with 10 µL CellKine media 
(Helvetica Healthcare) on day 3 and fresh media containing 
20 IU/mL IL-2 on days 7 and 10, as previously described 
[15]. The re-call antigen tuberculin purified protein deriva-
tive (PPD) (Statens Serum Institut) and the mitogen phyto-
haemagglutinin (PHA) (Sigma–Aldrich) were used as posi-
tive controls for T cell activation.
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Depletion of  CD25hi regulatory T cells
PBMC were resuspended in 80 µL MACS buffer (PBS, 
0.5% bovine serum albumin, 5 mM EDTA) per  107 cells, 
and 20 µL anti-human CD25 coated beads added (Milte-
nyi Biotec). Cells were incubated for 15 min at 4  °C, 
washed and resuspended in 500 µL MACS buffer. MS 
columns were used for positive selection, both effluent 
 CD25hi-depleted and labelled  CD25hi cells were collected. 
The efficiency of depletion was confirmed by flow cytom-
etry. Cells were washed twice before use.
IFN‑γ ELISpot
ELISpots were performed as previously described [15]. 
Briefly, ELISpot plates (Merck Millipore) were coated over-
night with anti-human IFN-γ capture antibody (MabTech). 
Wells were washed with sterile PBS to remove excess 
Fig. 1  Mapping HLA-DR-restricted 5T4 epitopes. a Forty-one 20mer 
peptides, overlapping by 10 amino acids and spanning the entire 
5T4 protein, were incorporated into a peptide pool matrix, whereby 
each peptide was placed in two pools to aid identification. b Fol-
lowing short-term culture of PBMC isolated from healthy donors 
(n = 9) and CRC patients (n = 16), 5T4-specific T cell responses 
were measured by IFN-γ ELISpot, and the number of IFN-γ+ spot-
forming cells (SFC) per  105 cultured PBMC to each peptide pool 
collated. c HLA-DR heatmap analysis was performed on all patients 
and healthy donors shown in b, in addition to patients and healthy 
donors used in an earlier study where identical peptide pool experi-
ments were performed [15]. Grey boxes indicate where a putative 
5T4-specific response (positive according to pooling matrix analysis) 
has been identified in that individual, example is shown for all HLA-
DRB1*01+ donors. Donor status is indicated by the coloured box, 
green (healthy donors) and orange (cancer patients). d This analysis 
was repeated for all individuals stratified by HLA-DRB1-type. The 
heatmap illustrates the proportion of individuals putatively respond-
ing to each 5T4 peptide
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antibody and RPMI containing 5% AB serum was added 
for 1 h at 37 °C. PBMC lines cultured in triplicate were 
pooled, washed and plated in the absence or presence of the 
corresponding 5T4 peptide pool or single peptide. Following 
18 h of incubation at 37 °C, 5%  CO2, cells were removed, 
plates were washed with PBS and secondary biotinylated 
anti-human IFN-γ antibody was added. Wells were washed 
with PBS followed by the addition of streptavidin–alkaline 
phosphatase (Mabtech). After incubation at room tempera-
ture, wells were washed and spots were developed by the 
addition of a colorimetric substrate kit (Bio-Rad). The reac-
tion was stopped after 15 min, and wells were washed in 
water. Spots were counted using an automated reader (Auto-
immun Diagnostika GMBH, A.I.D.). Counting was checked 
manually using the ELISpot 5.0 software. The number of 
spots was normalised to  105 PBMCs. Positive cultured 
responses were identified as having at least 25 spot-forming 
cells (SFC) per  105 PBMC, after subtraction of the back-
ground, and an increase of at least double the number of 
spots above background.
Antibody blocking assays
To determine HLA restriction, IFN-γ secretion was meas-
ured in ELISpot assays in the presence or absence of block-
ing antibodies. 10 µg/mL of anti-HLA-A,B,C (clone w6/32, 
Biolegend), anti-HLA-DQ (clone 1A3, Leinco) and/or anti-
HLA-DR (clone L243, Biolegend) antibodies were added to 
5T4-expanded T cells in ELISpot assays. 5T4 peptides were 
added following 1 h incubation with blocking antibodies.
Statistics and graphical analysis
GraphPad Prism Version 7 was used for all statistical anal-
yses. Mean values were used for all appropriate results. 
Unpaired t tests were used to analyse quantitative differences 
between different groups of CRC patients or when compar-
ing healthy donors and CRC patients. FlowJo version 10 was 
used to analyse flow cytometry data.
Results
Detection of pre‑existing 5T4‑specific  CD4+ T cells 
in healthy donors and CRC patients
The peptide specificity of Th1 and Treg cells recognising 
oncofoetal antigens has not been extensively studied in vitro, 
possibly due to the scale of experimental assessment neces-
sary to get an accurate picture of responses across multiple 
donors and HLA alleles. In silico techniques are available, 
but these ultimately need to be validated in vitro, and simply 
account for peptide HLA binding, not the potential Th1/Treg 
make up of responding populations which differs between 
groups such as cancer patients and healthy donors. Since the 
goal of this study was to identify regions of the 5T4 protein 
able to induce IFN-γ+ T cells in a diverse population, we 
first took a high throughput approach using IFN-γ ELIS-
pot assays with a short incubation time, low PBMC number 
and pools of peptides (as indicated in the matrix shown in 
Fig. 1a). Responses were measured in healthy individuals 
and individuals with CRC. Amongst all healthy donors, the 
strongest overall response was observed against peptide pool 
J with a mean response of 147 IFN-γ-producing cells/105 
cultured PBMC. The weakest overall response was directed 
against peptide pool F with a mean response of 15 IFN-γ-
producing cells/105 cultured PBMC (Fig. 1b). A remarkably 
similar profile was observed amongst CRC patients, with 
the highest mean IFN-γ+ T cell response again being pool 
H, and the weakest mean response in pool F. Compared to 
CRC patients, higher percentages of 5T4-reactive healthy 
donors were observed for all the peptide pools (Fig. 1b), in 
line with previous observations from our laboratory examin-
ing responses to the 5T4 protein [15].
Correlating HLA types of patients and healthy 
donors with peptide‑specific T cell responses
Since the number of reported 5T4-derived peptide epitopes 
is very limited, comprehensive mapping of T cell epitopes 
was conducted to further assess the usefulness of 5T4 to 
create peptide-based vaccines. We directed our analysis 
towards peptides to which reactivity patterns were associated 
with HLA-DR alleles. Therefore, responses to all putative 
5T4 peptides identified from the peptide pool matrix (see 
example in Supplementary Fig. 2) were mapped according 
to donor HLA-DRB1 genotype. In addition, this eliminated 
peptides which may have been overestimated by the pool-
ing matrix methodology, or were presented by HLA mol-
ecules other than HLA-DR. After grouping together all 
patients expressing the same DRB1 allele (example shown 
for DRB1*01 group in Fig. 1c, remaining HLA types shown 
in Supplementary Fig. 3), heatmaps revealed that specific 
sets of putative peptides associate with DRB1*01, *15, 
*03, *04, *07 and *13 alleles (Fig. 1d). Screening of the 
entire 5T4 amino acid sequence revealed four immunogenic 
regions:  5T411–40 (peptides 2–3),  5T461–100 (peptides 7–9), 
 5T4191–300 (peptides 20–29) and  5T4371–410 (peptides 38–40). 
These regions contain overlapping peptides with a reactivity 
greater than 21% (blue, dark blue or red squares) associ-
ated with at least three HLA-DRB1 alleles. In particular, 
peptides 20 and 21 were highly reactive, being recognised 
in more than 41% of DRB1*03+ donors, as well as 21–40% 
of DRB1*01, DRB1*04 and DRB1*07 donors. In contrast, 
amino acid regions 131 to 200 (peptides 14–19) and 301 
to 370 (peptides 31–36) contained the fewest epitopes as 
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indicated by the relatively low proportions of individuals 
responding to peptide pools C and F.
By analysing data across multiple donors using an HLA-
DR focused heatmap approach, we were able to identify the 
broad patterns of reactivity to 5T4. This overcame natural 
donor to donor differences and variations in reactivity (e.g. 
between three DRB1*01+, *04+ donors, Fig. 1c) that likely 
reflected differences in patient status, age and tumour stage 
[15]. This analysis emphasised that putative epitopes mediat-
ing 5T4 immunogenicity across the population (DRB1*03, 
DRB1*01, DRB1*04 and DRB1*07 are estimated to 
cover > 50% European American Population [17]), are not 
randomly distributed, but are focused in distinct regions of 
the protein. In the case of self-antigen, such areas have been 
hypothesised and extensively identified in silico [18–20], 
but comprehensive in vitro mapping studies of TAAs such 
as 5T4, are rare, despite their importance to immunotherapy.
Detailed analysis of individual peptide responses
Following identification of immunogenic regions, pep-
tides were selected for further investigations based on two 
essential criteria: (i) in vitro putative T cell reactivity in 
greater than 21% of donors for three HLA-DRB1 groups 
(from Fig. 1d) and (ii) in silico predicted binding to more 
than two HLA-DRB1 molecules in NetMHCII 2.2 [21] and 
IEDB [22] prediction algorithms (Supplementary Fig. 1). 
Based on this initial criterion, 14 candidate peptides were 
selected: peptides 2, 3, 15, 20 to 29 and 38. Furthermore, 
three peptides which showed in vitro reactivity across two 
HLA-DR groups were added based on the results of NetM-
HCII 2.2 [21] and IEDB [22] prediction algorithms: Peptides 
10 and 12 were predicted to be strong binders to between 
two and six HLA-DR molecules by either algorithm; p11 
was predicted to bind to fewer HLA-DR molecules but was 
included as it overlapped with both peptides (Supplementary 
Fig. 1). In total, 17 peptides were taken forward for further 
analysis.
In healthy donors, all peptides except for p15 induced 
IFN-γ production, the most commonly recognised being 
p12 (78%), p38 (67%), p20 (63%), p2 (56%) and p26 (50%) 
(Fig. 2a). In CRC patients, all peptides other than p11 and 
p29 induced a response, the most commonly detected being 
p38 (35%), p2 (33%), p3 (28%) and p28 (28%) (Fig. 2a). 
Fig. 2  Characterising peptide-specific 5T4 T cell responses gener-
ated by healthy donors and CRC patients. The percentage of healthy 
donors and CRC patients who had positive responses to each candi-
date 5T4 peptide (a) and the response rate to all peptides (b). c The 
mean IFN-γ+ T cell response to each candidate peptide, defined as 
the number of SFC/105 cultured PBMC, amongst healthy donors 
and CRC patients. The mean T cell response and response rate (%) 
amongst healthy donors (d) and CRC patients (e) is graphed together. 
Peptides which are recognised with high frequency (> 50%) in 
healthy donors are highlighted in green. f PBMC generating 5T4 pep-
tide specific responses amongst all donors were re-stimulated with 
the 17 immunogenic 5T4 peptides in the presence of MHC blocking 
antibodies (L243, 1A3 and W6/32 which block HLA-DR, HLA-DQ 
and HLA-A/B/C respectively). Significant differences are indicated 
(***P < 0.0001). Results are expressed as the number of IFN-γ+ 
SFC/105 cultured PBMC after subtracting background spots
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Peptides 10 and 12 were more immunogenic than p11, as 
predicted by the algorithms. For all peptides tested, the per-
centage of responders was significantly higher in healthy 
donors than in CRC patients (HD 36.0% ± 5.1 vs. CRC 
18.8% ± 2.7, P = 0.0079; Fig. 2b). This is consistent with 
early observations using peptide pools (Fig. 1).
The mean IFN-γ+ T cell response generated to each 
candidate 5T4 peptide by all donors was also calculated. 
Although there was a trend for CRC patients to mount higher 
IFN-γ+ responses over healthy donor controls, this was not 
significant (HD 70.4 SFC ± 8.1 vs. CRC 98.1 SFC ± 18.2, 
P = 0.16; Fig. 2c). Therefore, whilst the overall response rate 
to 5T4 peptides was lower in CRC patients, the mean T cell 
response mounted tended to be higher. Based on the mag-
nitude of positive responses and response rates (Fig. 2d, e), 
peptides 2, 12, 20, 26 and 38 emerge as immunodominant 
5T4 peptides in healthy controls (≥ 50% of donors, shown 
by the green dotted line in Fig. 2d). All five peptides are also 
recognised by CRC patients but to a noticeably lesser extent 
(5–38%). The same trend was observed for the other pep-
tides, except for p3 and p28, where responses were always 
less frequent or lower in magnitude for CRC patients (further 
details of immunogenic peptides in Supplementary Table 2).
To assess the extent of HLA-restriction in responses 
to our group of candidate peptides, we performed HLA 
blocking assays in both CRC patients and healthy donors 
(Fig. 2f). There was at least a 50% reduction in IFN-γ+ T cell 
response when testing individual peptides in the presence of 
anti-HLA-DR blocking antibody (L243) (Fig. 2f). In con-
trast, addition of anti-HLA-DQ (1A3) or anti-HLA-A/B/C 
(W6/32) did not affect peptide responses generated in any 
instance. This result validated our allele focused screening 
approach, and confirmed that most responses were mediated 
by HLA-DR.
5T4‑specific Treg epitopes
We have previously demonstrated that CRC patients have 
higher numbers of Treg with a suppressive phenotype rel-
ative to healthy individuals [7, 15, 23] and that anti-5T4 
responses are more likely to be controlled by these cells in 
CRC patients. Here, we set out to determine whether pep-
tides stimulating an IFN-γ T cell response also stimulated 
Treg. To do this,  CD25hi cells were depleted from PBMCs 
using Miltenyi MACS beads and T cell responses to each 
peptide were compared in depleted and non-depleted cul-
tures. As shown in Fig. 3a–c, this method of depletion 
always significantly decreased the proportion of  CD25hi 
cells (before: 5.20% ± 1.18 vs. after: 0.49% ± 0.16, Fig. 3a, 
b) corresponding with a decrease of  Foxp3+ cells (before: 
11.16% ± 1.28 vs. after: 3.79% ± 0.80, Fig. 3c).
In CRC patients, responses to the 17 candidate peptides 
were assessed in cultured IFN-γ+ ELISpot assays pulsed 
with single peptides, in the presence or absence of  CD25hi 
T cells. With respect to the immunodominant peptides 2, 12, 
20, 26 and 38, new or increased responses were observed 
against peptides 2, 12 and 38 in at least one donor (Fig. 3d) 
indicating that at least in some donors, the same peptides 
could induce both Treg activity and IFN-γ producing T cells. 
Other instances of Treg suppression were observed for pep-
tides 3, 22, 23 and 24. Finally, responses to p28, which were 
observed largely in CRC patients (Fig. 2d, e), were reduced 
by Treg-depletion (Fig. 3e). Where existing responses were 
abrogated by Treg depletion (also occurred for peptides 3, 
10, 15, and 24, in some donors), this appeared to be inde-
pendent of donor HLA-type (Supplementary Table 3). The 
most likely explanation was a depletion of activated effector 
cells with high CD25 expression.
Overall, Treg-mediated control of 5T4-specific responses 
was observed in 8/14 (57.1%) CRC patients tested. These 
data provide evidence for Treg-mediated inhibition of Th1 
cells of the same peptide specificity but also indicate that 
some but not all peptides induce Treg responses. Whether 
the same 9mer epitopes within each 20mer were the focus of 
Th1 and Treg immunogenicity cannot be conclusively deter-
mined from the experimental data. However, for the immu-
nodominant peptides (2, 26 and 38) the same core 9mer 
was predicted to bind with highest affinity to all HLA-DR 
alleles, suggesting within certain peptides a single epitope 
may dominate HLA-DR mediated immunogenicity (Sup-
plementary Table 4).
Our reductive approach indicates that Treg can suppress 
in an antigen-specific manner and likely share peptide spec-
ificity with conventional T cells. However, it is also pos-
sible that Treg may be stimulated by a given peptide but 
suppress in an antigen non-specific manner. An experiment 
was, therefore, designed to determine whether those 5T4 
peptides that rarely stimulate IFN-γ production (as indicated 
in Fig. 1d), might in fact represent Treg epitopes. Peptides 
5, 16, 18 and 19, which rarely induced IFN-γ responses 
(< 20% of donors), were selected and added together to 
make a putative ‘5T4 Treg pool’. As strong responses to the 
control antigen PPD were not impacted by addition of this 
Treg pool (Supplementary Fig. 4), we hypothesised that the 
suppressive effect of the 5T4 Treg pool may only impact 
responses to other 5T4 peptides. Cultured responses to pep-
tide 2, to which most healthy donors respond (predicted to 
bind HLA-DRB1*01), were used to design an in vitro sup-
pression assay.
PBMC from three healthy DRB1*01+ donors were 
expanded to peptide 2 (twelve replicates per donor) in the 
presence or absence of the putative Treg pool (Fig. 3f). 
Although some donor variation in response magnitudes were 
observed, no significant differences in the number of posi-
tive lines, or magnitude of responses in the presence of the 
putative Treg pool were observed. Thus, we hypothesised 
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that these peptides were not stimulators of epitope-specific 
Treg, but simply poorly immunogenic relative to the rest of 
the 5T4 protein.
Discussion
It has become increasingly clear that the oncofoetal antigen 
5T4 is a promising T cell target in the context of CRC. In a 
recent clinical study, patients with inoperable CRC received 
either cyclophosphamide alone to deplete Treg, a vaccine 
comprising 5T4-expressing modified vaccinia Ankara (Tro-
Vax) or a combination of both [16]. Both treatments were 
shown to independently induce 5T4-specific responses 
which were associated with prolonged patient survival. We 
set out to deconstruct these highly beneficial responses fur-
ther, first by identification of specific peptides responsible 
for IFN-γ+ immunogenicity, and second by evaluating the 
extent and specificity of Treg mediated suppression. Such 
knowledge could be utilised to improve therapeutic strate-
gies built on responses to TAAs by altering the balance in 
activity of Th1 and Treg populations.
Fig. 3  Regulatory T cells do not suppress all effector anti-5T4 T cell 
responses. a Whole PBMC were depleted of  CD25hi T cells, a repre-
sentative example of the FACS plots confirming adequate depletion 
is shown. The proportion of  CD4+ T cells expressing  CD25hi (b) or 
Foxp3 (c) in all donors is shown before and after depletion. PBMC 
and Treg-depleted PBMC from CRC patients were stimulated with 
each of the five immunogenic peptides (d) and 12 candidate peptides 
(e). The IFN-γ spot-forming cells/105 cultured PBMC, after subtrac-
tion of background spots, was measured before and after the depletion 
of  CD25hi T cells. f PBMC were cultured with 5T4 peptide 2, with 
or without the ‘Treg peptide pool’ before restimulation with peptide 
2 alone on IFN-γ ELISpot. Assay was carried out in three healthy 
donors (twelve PBMC lines per condition)
 Cancer Immunology, Immunotherapy
1 3
Using a panel of overlapping peptides covering the 5T4 
protein and blood samples from a cohort of CRC patients 
and healthy controls, we found 5 immunogenic regions 
within the 5T4 protein and 17 peptides recognised by T cells 
from healthy controls and, to a lesser extent, CRC patients. 
Further analysis revealed a hierarchy of peptides recognised 
by healthy donors and CRC patients, with p2, p20 and p38 
consistently immunogenic in both groups. These peptides, 
together with p3, p26 and p28, to which responses were 
also often observed in CRC patients, form a useful group of 
peptides for tracking 5T4-specific T cells responses during 
disease progression and in response to vaccination. Only a 
few TAAs with high immunogenicity across the population 
have been reported previously; NYESO-1 [10], MELOE-1 
[24–26] and Survivin [9]. Recently, the discovery and char-
acterisation of novel TAAs has been superseded by a strong 
focus on the discovery and characterisation of neoepitopes, 
which although efficacious at the level of the individual, are 
not useful for universal cancer vaccines applicable to the 
population.
The pan-HLA-DR nature of the immunogenic regions 
detailed here confirms the suitability of 5T4 for cancer vac-
cination. The widespread in vitro immunogenicity of key 
regions may arise from several competing factors: first, 
the long length of the 5T4 peptides used (20 amino acids) 
make it possible that several epitopes of different 9-mer core 
sequences (with distinct HLA-DR restriction) are present 
within these peptides enabling many donors of different 
HLA types to respond. Second, the peptides identified may 
be promiscuous and thus able to bind various HLA-alleles. 
It has previously been shown that a short epitope (14-mer) 
derived from HCA587 tumour Ag can stimulate T cells in 
the context of more than one HLA class II allele [27], while 
for viral antigens such as influenza haemagglutinin, the most 
immunogenic HLA class II epitope exhibits strong binding 
to nearly all HLA-DR alleles [28]. Thirdly, recognition of 
these peptides may have arisen by T cell cross-reactivity 
with common microbial epitopes [29]. The most immuno-
genic peptides may exhibit molecular mimicry to highly 
immunogenic microbial peptides when presented in the con-
text of specific HLA alleles. Such microbial epitopes could 
have primed large Th1 memory pools during infection, only 
a fraction of which would need 5T4 cross-reactive TCRs to 
elicit the immunogenicity described here.
While T cell responses to 5T4 were readily observed 
in CRC patients, these were diminished compared to 
those observed in healthy controls. It is clear, therefore, 
that mechanisms of peripheral tolerance do not prevent 
induction of 5T4-specific T cell responses but that these 
responses are suppressed due to the presence of the can-
cer. Several cancer-associated immunosuppressive mecha-
nisms have been described including expression of co-
inhibitory receptors by effector T cells, suppression by 
Treg, myeloid-derived suppressor cells and/or immuno-
suppressive cytokines. It is also possible that CRC patients 
have a more limited TCR repertoire of 5T4-specific T 
cells, as has been shown for the TRAG-3 tumour Ag in 
melanoma and breast cancer patients [30].
This study focused on Treg-mediated immunosuppres-
sion since we have previously observed that Treg do sup-
press 5T4-specific T cell responses in CRC patients and 
that this is more likely to be observed during the later 
stages of disease. Examining T cell responses to individual 
peptides as described herein enabled us to examine the 
peptide specificity of Treg in CRC patients. Our results 
revealed that Treg and Th1 cells share the same specificity 
for some, but not all 5T4 peptides. Furthermore, whether 
an individual peptide is recognised by Treg and/or Th1 
cells varies between patients, rendering the possibility of 
creating a universal 5T4 vaccine including beneficial T 
helper peptides and excluding detrimental Treg epitopes of 
the same specificity very challenging. Some studies have 
reported that whilst Treg are antigen-specific, their sup-
pressive activities are antigen non-specific. For instance, 
upon activation, HPV-specific Treg can suppress influenza 
specific-Th1 cell activity [31]. Whilst a previous study by 
Bonertz and colleagues showed that Treg can recognise 
several tumour Ags, however, their ability to suppress in 
an Ag non-specific manner was not tested [32]. As well as 
examining the capacity of Tregs to be activated in response 
to peptides recognised by Th1 cells, we tested whether 
regions of the 5T4 protein, which consistently failed to 
activate IFN-γ+ T cells, contain peptides recognised by 
Treg. These assays did not show non-immunogenic regions 
to harbour Treg epitopes, but instead reiterated that Th1 
and Treg populations must share some specificity and the 
balance between populations likely determines the mag-
nitude of the overall response [33].
Overall, this study has revealed numerous peptides, 
which may be recognised by both Th1 and Treg cells. 
These data are reminiscent of those published previ-
ously by Welters et al. who showed that vaccination with 
HPV-derived long peptides induce HPV-specific Th1 and 
Treg responses in patients with different type of cancers 
[11, 12] where a high Th1 to Treg ratio was predictive 
of a good clinical response. In this case, a combination 
of vaccine and an agent to downmodulate Treg might be 
required. Therapeutic agents that may selectively target 
 CD25hi populations including Treg, such as cyclophos-
phamide, are attractive for this purpose. Studies of chronic 
infection in mice have shown that the context of antigen 
exposure alters the balance between Th1 and Treg cells of 
a given specificity [33]. A better understanding of the rules 
governing this balance should prove useful for inform-
ing strategies designed to minimise induction of tumour 
antigen-specific Treg cells.
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